Back to Search
Start Over
[Renin-angiotensin system (RAS) as new molecular therapeutic targets in prostate cancer].
- Source :
-
Nihon rinsho. Japanese journal of clinical medicine [Nihon Rinsho] 2012 Sep; Vol. 70 (9), pp. 1604-12. - Publication Year :
- 2012
-
Abstract
- Angiotensin II and AT1 receptor could be involved in the growth of androgen independent prostate cancer since we found the higher expression of AT1 receptor in prostate cancer tissue than in normal tissue. Angiotensin II directly and indirectly stimulates the growth of prostate cancer cells and stromal cells including angiogenic cells. ARBs experimentally inhibited the proliferation of cancer cells and angiogenesis. The administration of ARBs for castration resistant prostate cancer (CRPC) induced the decline of serum prostate specific antigen (PSA) and the improvement of performance status in cachexic CRPC patients. These results support the hypothesis that an intrinsic RAS exists in the prostate gland and it is likely that ARBs are useful molecular targeting agents for CRPC.
- Subjects :
- Angiotensin II metabolism
Humans
Male
Prostatic Neoplasms metabolism
Prostatic Neoplasms prevention & control
Angiotensin Receptor Antagonists therapeutic use
Molecular Targeted Therapy
Prostate-Specific Antigen metabolism
Prostatic Neoplasms drug therapy
Renin-Angiotensin System drug effects
Subjects
Details
- Language :
- Japanese
- ISSN :
- 0047-1852
- Volume :
- 70
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Nihon rinsho. Japanese journal of clinical medicine
- Publication Type :
- Academic Journal
- Accession number :
- 23012811